Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins

Open-label,non-controlled study design with three visits (pre-treatment/baseline, treatment day 14 and day 28). Administered Esarin Gel twice daily for 28 days in subjects with chronic venous insufficiency rated between CEAP 0 and 3 or varicose veins combine superficial vein thrombophlebitis, in comparison to the pre-treatment.

• Inclusion Criteria:

• Patients of both sexes, aged above 20 years old.
• The patient has confirmed his/her willingness to participate in the study, after being informed about all the aspects of the study that might be relevant for his/her decision to participate, and has signed and dated the informed consent form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC).
• Presence of chronic venous insufficiency which is rated between functional classes CEAP 0 and 3.(CEAP Classes: C0:no visible or palpable signs of venous disease, C1:telangiectasies or reticular veins. C2 :apparent Varicose veins, C3 :Edema)
• Diagnosed with superficial vein thrombophlebitis and have skin reaction by redness, swelling, fever and pain symptoms.
• Exclusion Criteria:

• Known allergy to the product's ingredients
• pregnant or breastfeeding
• patient is joining to any other clinical trail
• Patient has not sign the informed consent form
• Deep vein thrombosis
• Cellulitis
• Stasis dermatitis
• The patient is taking non-steroids anti-inflammatory drugs( include oral ,topical creams or patch form)